Copolymer/graphene oxide nanocomposites as potential anticancer agents

A synthetic style for preparing a graphene oxide/poly(ethyleneglycol)-b-poly(2-hydroxyethyl methacrylate-g-lactide)2 nanocomposites (GO/PEG-b-poly(HEMA-g-LA)) is via reversible addition fragmentation chain transfer polymerization. The characterization of GO/PEG-b-poly(HEMA-g-LA)2 nanocomposites was confirmed by scanning electron microscopy, ultraviolet–visible (UV–Vis) spectroscopies and dynamic light scattering measurements. This system as a safe nanovehicle has been studied for cancer therapy. Adult male rats were randomly allocated into five groups. Rats received normal saline, doxorubicin (DOX 12 mg/kg), and GO/PEG-b-poly(HEMA-g-LA)2@DOX at 6, 12, or 24 mg/kg via intraperitoneal rout daily for 4 weeks. Finally, serum samples were obtained to determine serum biochemical parameters. After euthanasia, liver and kidney samples were preserved in formalin to perform histopathological analysis.